Skip to content
MarketScale
‹ Back to IndustriesHealthcare

Ranfac is Celebrating the Wins of 2018 and Looking Forward to a Great 2019!

As a single source manufacturer, Ranfac handles everything from raw material to final packaging in one location. We’re proud to boast that our products have been 100% manufactured in the U.S. since 1888. We enjoy our wonderful partnerships in the healthcare and medical device industries and are happy to celebrate 2018 and its accomplishments, even…

This story was produced through MarketScale. See how Healthcare teams put it to work with Executive Thought Leadership.

Share

Get featured

Want to get featured in MarketScale Healthcare?

Create a free MarketScale workspace and get your company's expertise featured across our Healthcare coverage. No credit card, no demo required.

Start free

As a single source manufacturer, Ranfac handles everything from raw material to final packaging in one location. We’re proud to boast that our products have been 100% manufactured in the U.S. since 1888. We enjoy our wonderful partnerships in the healthcare and medical device industries and are happy to celebrate 2018 and its accomplishments, even a couple of months into the year. It’s never too late to get excited about innovation! We wanted to take an opportunity to look back at some of the wins of 2018 and share our plans for 2019 in the areas of operational improvements, regulatory and quality developments, and sales and marketing achievements.

Operational Improvements

In 2018, Ranfac celebrated some important operational improvements. We completed the design and build of our part payoff systems to feed the UR5 robot for pick-and place-secondary operations, as well as a new Ultrasonic Cleaning line. The innovative new cleaning line offers real-time monitoring of critical levels of process fluids for soaps and rinsing operations: a state-of-the-art triple cascade rinse with continuous Deionized water flow. The installation of a HEPA filter dryer was employed to eliminate the use of isopropyl alcohol as a drying agent, making for a greener operation. In addition, the company installed a cutting-edge electrolytic needle grinder, typically capable of producing parts 3X faster than conventional grinding while producing a burr-free part in a single operation. To round out 2018, Ranfac added epoxy floor surfacing to our Ultrasonic Cleaning room and our Molding departments to further protect and prevent particulates while providing a more contemporary finish to our manufacturing spaces.

Looking forward to 2019, Ranfac is installing a new laser welder that uses autonomous feature recognition to put the weld on the required seam, regardless of component size variance. A fully programmable 4-axis machine, the new welder has built-in data logging for critical laser output parameters. Furthermore, a lean manufacturing initiative is underway to remove defunct items from warehouse and manufacturing spaces. The company will welcome a proliferation of robotic manufacturing in our molding department for three shifts of continuous production. Offering clear cost benefits, the molding cycles will equally advance to Scientific Molding Standards with more consistent processing times of plastic through molding feed throats.

Regulatory and Quality Developments

In 2018, while continuing to provide superior products to the European markets and maintaining a robust technical file for each product, Ranfac once again proved our ability to adapt to the more stringent CE certification requirements. We’ve also seen tremendous growth in human resources. New staff acquisitions have proven to be successful fits within the company, and our team of highly qualified professionals has the necessary skills to propel continued progress. Ranfac has also successfully executed a cleaning re-validation, reflecting that our products meet the requirements of implantable grade products, and exemplifying that our water system is as clean as pharmaceutical grade water. The system can now be monitored for process parameters that will inform us when detergents or DI water are outside specifications, allowing Ranfac to react before there are any digressions.

In 2019, we are launching new products within our newly revised design process, which will yield more robust Design History Files that can be utilized to more easily register products through the FDA and the EU. In addition, Ranfac is purchasing and validating a new laser welder. Furthermore, 2019 will see the procurement of HEPA filtration in molding, QC, and assembly to increase the number of controlled environments within the walls of Ranfac and increase the cleanliness of our devices.

Sales and Marketing Updates

2018 was an impressive year for our company in terms of sales and marketing. Last year, Ranfac launched our proprietary Lipo-Pro™ Adipose Processing System, which received excellent feedback from early adaptors and is expected to see tremendous growth in 2019. Additionally, Ranfac published critical data on Marrow Cellution and began a partnership with Dr. Saleh.

We also anticipate important new product development in 2019. We will begin testing on a proprietary Platelet Rich Plasma (PRP) System with a planned launch in the 3rd quarter of 2019. Ranfac also hopes to round out our autologous biologic portfolio, offering best-in-class solutions for Bone Marrow Aspirate, Fat Grafting, and PRP. We will finalize the development of our next generation Bone Marrow Harvesting Product and incorporate Marrow Cellution™ technology to better target stem cell niches along the inner-bone surface. And, of course, we are looking forward to strengthening current partnerships and forming new relationships with pioneers in the medical device industry and throughout the healthcare ecosystem.

Ranfac offers integrated solutions for product design & development, manufacturing process development, regulatory approval, and single source manufacturing. Further, eschewing outsourcing, we handle each phase of product design and development ourselves right here in America.

At Ranfac, we offer integrated solutions for product design & development, manufacturing process development, regulatory approval, and single source manufacturing. Click here to follow the exciting developments at Ranfac for 2018, 2019, and beyond!

Your experts belong here

Every story in MarketScale Healthcare starts with a company putting its clinicians, service-line leaders, and field engineers on the record. Buyers are already reading this topic. The only question is whose experts they find.

Service-line buyers vet vendors quietly, and your clinicians become the proof they find while doing it.

Get your team featuredSee how it works15 minutes, straight to a calendar.

Follow Healthcare Insights

Get new expert content in your inbox.

Healthcare: are you visible to AI?

Before they reach out, Healthcare buyers ask AI engines which vendors to trust. Explore how your experts, customers, and partners can become useful content for buyers and AI search.

Free plan

You just read one Healthcare expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your clinicians, service-line leaders, and field engineers into the articles, video, and social content Healthcare buyers are searching for. Create a free workspace and see it with your own people. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale workspace, up to 10 people
One professional video edit a month for qualifying companies
Media requests to your crowd, remote recording, AI writing tools
$0, no credit card, nothing that expires

More Healthcare Insights

July partnerships show hospitals aligning without ownership change

July partnerships show hospitals aligning without ownership change

A July McDermott Will & Schulte analysis and four July partnership announcements tracked by Becker’s Hospital Review point to affiliation models that stop short of mergers. St. Christopher’s signed a nonbinding letter of intent with Nemours, Jefferson and Temple; Palomar UC San Diego Health began operating July 1 under a joint powers authority. Several announcements explicitly rule out ownership change, shifting the work to contracts covering governance and other terms.

  • 01In an alliance, the contract does the integrating that an org chart does in a merger: McDermott Will & Schulte says governance design, exclusivity, antitrust review, community commitments and exit rights all have to be settled before signing.
  • 02Purchasing is now explicitly on the table in at least one no-ownership deal, the St. Peter's Health and Billings Clinic-Logan Health talks in Montana, which means shared supply contracts can arrive without a change of control.

Sep 19, 2026

Eye telemedicine hits limits without home retinal imaging

Eye telemedicine hits limits without home retinal imaging

An Ophthalmology Times commentary by T.Y. Alvin Liu, Ferdinand Hui and Phillip Phan sorts eye patients into three telemedicine tiers by clinical need. Patients needing regular OCT scans benefit less unless a home device can send the image. Video tools already sit inside Epic and Cerner; the deciding purchase for retina clinics is the imaging device in the patient's living room.

  • 01The dividing line for eye telemedicine is imaging, not video: patients who need regular OCT scans benefit less from remote visits unless a device at home can send the scan, so a video license alone shifts few of those encounters.
  • 02The provider-side requirement, a HIPAA-compliant secured video platform, was already built into Epic and Cerner by 2020; the patient-side requirements (1.5 MB up and down bandwidth, a quiet private room, comfort with the technology) sit outside the health system's control and are the ones worth screening for at scheduling.
  • 03Self-administered home color fundus photography for tracking non-proliferative diabetic retinopathy was named as the nearer route into retina telemedicine; home OCT for wet AMD is the harder gate and the device to watch.

Sep 19, 2026

Value-based care reaches a quarter of revenue at 30% of surveyed health organizations

Value-based care reaches a quarter of revenue at 30% of surveyed health organizations

Wolters Kluwer Health argues value-based care software is judged on whether customers hit incentive thresholds and avoid penalties. A Fierce Healthcare-reported survey it cites puts value-based care at a quarter or more of revenue for 30% of organizations. The analysis is a vendor publication that ends by pitching its own UpToDate Connect API.

  • 01The sharper question for any population health or care coordination platform is whether it changes what a clinician does at the moment of decision, or only reports afterward what happened. Wolters Kluwer's reading of the evidence is that many platforms still struggle with the first.
  • 02Vendors selling into value-based contracts now face a build-or-license decision on clinical content, because Wolters Kluwer names current, trusted content, consistent clinician adoption across sites, and a traceable link from guidance to quality metrics as the three hard problems.

Sep 18, 2026

Explore More Healthcare Insights

Read more expert perspectives from across Healthcare.

Browse Healthcare Hub

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Healthcare and beyond.

Book a 15-minute demo

Or call us. No forms required. We pick up. 214-945-2512